Donald E. Ingber | |
|---|---|
 Ingber in 2010 | |
| Born | 1956 |
| Academic background | |
| Education | Yale College and Yale Graduate School of Arts and Sciences |
| Academic work | |
| Institutions | Royal Marsden Hospital Harvard University |
| Notable students | Samira Musah Javier G. Fernandez |
Donald E. Ingber (born 1956)[citation needed] is an American cell biologist and bioengineer. He is the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University,[1] the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.[2] He is also a member of the American Institute for Medical and Biological Engineering, the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences.
Ingber is a founder of the emerging fields of biologically inspired engineering. He has made pioneering contributions to numerous other disciplines including mechanobiology, cytoskeletal biology, extracellular matrix biology, integrin signaling, tumor angiogenesis, tissue engineering, nanobiotechnology, systems biology, and translational medicine. Ingber has authored more than 470 publications in scientific journals and books, and is an inventor on more than 190 patents spanning anti-cancer therapeutics, tissue engineering, medical devices, drug delivery systems, biomimetic materials, nanotherapeutics, and bioinformatics software.
Ingber has been scientific founder of five companies: Neomorphics, Inc.,[3] a tissue engineering startup which led to clinical products through subsequent acquisitions (Advanced Tissue Sciences Inc.); Tensegra, Inc. (formerly known as Molecular Geodesics, Inc.,)[4] which 3D-printed medical devices; and most recently, Emulate, Inc.,[5] which formed to commercialize human "organs-on-chips" that accelerate drug development, detect toxicities and advance personalized medicine by replacing animal testing; Boa Biomedical, Inc. (originally known as Opsonix, Inc.),[6] which aims to reduce deaths due to sepsis and blood infections by removing pathogens from the blood; and FreeFlow Medical Devices, LLC, which develops special coatings for medical devices to eliminate the formation of blood clots and biofilms on materials.
- ^ Crow, James Mitchell (19 January 2015). "The man who built organs on chips" Archived 2018-07-02 at the Wayback Machine, Cosmos.
- ^ "Donald Ingber", Harvard Medical School.
- ^ "Neomorphics, Inc: Private Company Information". www.bloomberg.com. Retrieved 5 February 2015.
- ^ "Tensegra, Inc.: Private Company Information". www.bloomberg.com. Retrieved 5 February 2015.
- ^ "Emulate Launches to Commercialize Human Organs-on-Chips". www.businesswire.com. 28 July 2014. Retrieved 5 February 2015.
- ^ "Welcome to Opsonix". Opsonix Website. Retrieved 2019-01-10.